GlassScriptPhysician profile
Chrystal M Griffis
NPI 1033379706
$5,376.28
in general payments reported to CMS, 2019-2025
32 companies · $939 in 2025
The $939 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $889 · 2021: $911 · 2022: $980 · 2023: $616 · 2024: $832 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.23 | 2021-2025 | |
| Amgen INC. | $670.78 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $506.42 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $489.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $390.67 | 2024-2025 | Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $381.91 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $362.37 | 2022-2025 | |
| Pfizer INC. | $323.56 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $313.67 | 2019-2025 | Airsupra, Farxiga |
| Allergan, INC. | $159.61 | 2019-2020 | |
| Exact Sciences Corporation | $104.69 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $97.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.60 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $81.50 | 2020-2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Mannkind Corporation | $59.40 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $57.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $46.90 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $44.88 | 2024 | Gemtesa |
| Radius Health, INC. | $35.75 | 2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $33.77 | 2022 | |
| Philips North America LLC | $32.65 | 2024-2025 | Mcot, (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $30.35 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $29.41 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $21.79 | 2020 | |
| Medtronic USA, INC. | $19.74 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.43 | 2024 | Xifaxan |
| Pbg Puerto Rico LLC | $17.99 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.94 | 2022 | |
| Esperion Therapeutics, INC. | $15.08 | 2021 | |
| Mylan Specialty L.P. | $13.96 | 2024 | Yupelri |
| Astellas Pharma US INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrystal Griffis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.